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Purpose: Retinopathy of prematurity (ROP) is one of the leading causes of blindness, with retinal detachment occur-
ring due to oxygen toxicity in preterm infants. Recently, advances in neonatal care have led to improved survival 
rates for preterm infants, and ROP has increased in incidence. In the present study, we aimed to determine 
whether or not resveratrol exhibits protective effects in an animal model of ROP and in primary retinal cell cultures 
of neonatal rat via nitric oxide (NO)-modulating actions using western blotting and real-time PCR with inducible 
nitric oxide synthase (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) antibodies and mRNAs. 
Methods: In an in vivo oxygen-induced retinopathy (OIR) model, cyclic hyperoxia was induced with 80% O2 for one 
day and 21% O2 for one day from P1 to P14 in newborn Sprague-Dawley (SD) rats. Resveratrol was injected in-
travitreally for seven days and rats were sacrificed at P21. In vitro OIR primary retinal cell culture was performed 
using P0-2 SD rats. Hyperoxia injuries were induced through 100% O2 exposure for six hours. Western blotting 
and real-time PCR using iNOS, eNOS, nNOS antibodies and primers were performed in the rat model of ROP 
and the dispersed retinal cell culture. 
Results: In both in vivo and in vitro OIR, the expression of iNOS antibody and mRNA was increased and of eNOS 
and nNOS were reduced in the resveratrol-treated group. 
Conclusions: In conclusion, resveratrol appeared to exert retinal protective effects via modulation of NO-mediated 
mechanism in in vivo and in vitro OIR models.
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Retinopathy of prematurity (ROP) is a leading cause of 
blindness and a complex disease of the immature retina in 
premature infants. This disease affects approximately 80% 
of babies born with birthweights less than 1000 g [1]. 
Preservation of visual acuity in ROP usually requires abla-
tion of the peripheral retina via methods such as cry-
otherapy and laser photocoagulation therapy [2]. Because 
of these treatments the incidence of blindness was reduced 
by 25%. Clinical manifestations of ROP range from mild 
transient changes of the peripheral retina to severe pro-
gressive vasoproliferation resulting in scarring, retinal de-
tachment, and potential blindness. ROP includes all stages of 
disease such as acute (early) or chronic (late or cicatricial) 
stages, as well as late sequelae such as high myopia, stra-
bismus, amblopia, diplopia, glaucoma, cataract, viterous 
hemorrhage, and low vision [3]. Retrolental fibroplasia 
(RLF), the previous name for this disease, describes only the 
cicatricial stages. Given the current understanding of ROP, it 
is recommended that all infants born at less than 1500 g re-
ceive regular eye examinations starting at four weeks chrono-
logic age or 31 weeks postconceptional age, whichever is lat-
er [4]. 
After premature delivery, oxygen levels in postnatal tis-
sue are significantly increased compared to those in utero. 
Additionally, oxygen therapy further increases oxygen lev-
els in the developing retina. This hyperoxia results in 
vaso-obliteration and destruction of normal retinal vascular 
development. At that time, low insulin-like growth factor 
(IGF)-1 levels decrease and hypoxia inducible factor (HIF), 
as transcriptional factor for vascular endothelial growth fac-
tor (VEGF), and VEGF are also reduced. After the return to WT Kim and ES Seo. Resveratrol Effect on Oxygen-induced Retinopathy
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normal oxygen levels after the cessation of oxygen therapy, 
the nonperfused portions of the retina become hypoxic. 
Retinal hypoxia stimulates IGF-1, HIF, and VEGF before 
neovascularization. VEGF causes retinal neovascularization 
and retinal proliferation. VEGF results in extraretinal an-
giogenesis–stage 3 ROP at the vitreoretinal interface of the 
ROP ridge. Stage 3 ROP may resolve spontaneously, or 
may progress to traction retinal detachment and blindness. 
Further inhibition of IGF-1, HIF, and VEGF decreases reti-
nal neovascularization [5]. 
In the present study, an in vivo oxygen-induced retinop-
athy (OIR) model was designed using a rat model of ROP 
induced by cyclic hyperoxia, exposed to 80% O2 for one 
day and 21% O2 for another day from P1 to P14 of newborn 
Sprague-Dawley (SD) rats, as described by Penn et al. [6] 
Retinal detachment was identified using Hematoxylin and 
eosin (H&E) staining. An in vitro OIR model was designed 
using dispersed retinal cell cultures, as described by Seigel 
[7]. All cells were damaged by oxygen exposure for six 
hours. Photoreceptors, the major population of neuronal 
cells in retinal cell culture, were immunolabeled with inter-
photoreceptor retinoid-binding protein (IRBP) antibody. 
Resveratrol (trans-3,5,4'-trihydroxystilbene) is a phytoa-
lexin produced by a variety of plants such as grapes, pea-
nuts, and berries in response to stress, injury, ultraviolet irra-
diation, and fungal infection [8]. Resveratrol can be detected 
in the leaf epidermis and the skin of grapes [9]. The “French 
paradox,” the low incidence of coronary heart diseases in 
spite of a diet rich in saturated fats has been attributed to a 
number of contained polyphenols, including resveratrol 
[10].
 Resveratrol has some physiological effects, including 
prevention of lipid peroxidation in human LDL [11], in-
hibition of arachidonate acid metabolism [12], inhibition of 
platelet activity [13], and stimulation of NO production in 
endothelial cells to exert vasodilatory effect on blood ves-
sels [14].
We investigated resveratrol as a nitric oxide (NO)-mechanism 
modulator to evaluate the mechanisms of ROP based on 
molecular biology and pharmacological treatments in the in 
vivo OIR model, the rat model of ROP, and the in vitro OIR 
model, the hyperoxic injury of cultured dispersed retinal 
cells. Recent reports reveal that retinal damage also occurs 
via NO-mediated mechanisms. Previously, we recognized 
that resveratrol exhibits neuroprotective effects and car-
dioprotective effects via modulation of NO-mediated mech-
anisms [15,16].
In the present study, the protective ability of resveratrol 
was explored in an animal model of ROP and in primary ret-
inal cell cultures of neonatal rat retinas. We attempted to 
better define whether resveratrol is a promising treatment of 
ROP and has preventive mechanisms via NO-modulating 
actions using western blotting and real-time PCR with in-
ducible nitric oxide synthase (iNOS), endothelial NOS 
(eNOS) and neuronal NOS (nNOS) antibodies and mRNAs. 
Materials and Methods
Materials
Resveratrol, papain, glucose, and poly-D-lysine were pur-
chased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). 
Rabbit polyclonal IRBP and secondary goat anti-mouse or 
rabbit IgG-HRP antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal 
iNOS, rabbit polyclonal eNOS, and rabbit polyclonal nNOS 
antibodies were purchased from Assay Designs (Stressgen, 
Ann Arbor, MI, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl-tetrazolium bromide (MTT) was purchased from 
Duchefa (Haarlem, Amsterdam, Netherlands). Hanks' bal-
anced salt solution (HBSS), Eagle's Minimal Essential 
Medium (MEM), fetal bovine serum (FBS), and gentamicin 
were purchased from Gibco BRL (Grand Island, NY, USA). 
DNase I was obtained from Takara (Otsu, Shiga, Japan). 
Complete protease inhibitor cocktail tablets were purchased 
from Roche Applied Science (Mannheim, Germany). 
Enhanced chemiluminoscence (ECL) and a western blot-
ting detection system were purchased from Amersham 
Biosciences (Piscataway, NJ, USA). SUPEX was pur-
chased from Neuronex (Pohang, Korea).
Animal model of ROP (in vivo OIR)
Postnatal day 1 SD rats were obtained from Samtako 
(Osan, Korea) or HyoChang Science (Daegu, Korea). We 
implemented a cyclic oxygen exposure protocol that was 
modified from previous rat oxygen-induced retinopathy 
studies [6]. Hyperoxic experiments were conducted in an 
airtight polypropylene container 295×230×84 mm (3.9 L 
volume; Lock & Lock, Yongin, Korea) equipped with inlet 
and outlet ports. The inlet port received 100% medical grade 
oxygen and the airflow from the outlet was monitored for 
oxygen content using an oxygen monitor (Hudson RCI, 
Temecula, NC, USA). The oxygen levels remained above 
98% throughout the entire exposure period. The interior of the 
chamber was maintained at room temperature. Control ani-
mals were maintained in room air. The cyclic hyperoxic con-
ditions were performed at 80% O2 for one day and 21% O2 for 
another day from P1 to P14 in newborn SD rats. The drug was 
injected intravitreally (into the vitreous humour of the eye) 
once a day for seven days and the rats were sacrificed at P21.
The animals were divided into three groups. Group 1 (nor- 
moxia control, N, n=7) was not exposed to hyperoxia. Group 2 
(hyperoxia only, H, n=8) was subjected to hyperoxia without 
treatment. Group 3 (hyerpoxia+resveratrol, HR, n=8) was ad-
ministered resveratrol (30 mg/kg, intraperitoneal injection).
H&E stain
Histologic studies were performed seven days after hy-
peroxic insult. After sacrifice and intracardiac perfusion Korean J Ophthalmol Vol.24, No.2, 2010
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with saline, the rats’ eyes were removed, fixed in 4% paraf-
ormaldehyde, embedded in paraffin, and prepared for light 
microscopy. Four µm sections were mounted on glass 
slides. Sections were deparaffinized in xylene for 30 mi-
nutes and serially treated with 100% (5 minutes), 96% (10 
minutes), and 70% (10 minutes) ethanol. Slides were 
stained with hematoxylin, rinsed for a few seconds with wa-
ter to remove excess stain, placed in 1% eosin, then rinsed 
again briefly in water to remove the acid and washed 
through a successive series of 70%, 95%, and 100% ethanol 
at five minutes each. Finally, the slides were transferred to 
xylene for clearing, mounted, and cover slipped.
Primary culture of dissociated-dispersed retinal cells   
(in vitro OIR)
This study was performed in accordance with the ap-
proved animal use guidelines of the Catholic University of 
Daegu. Primary retinal tissue was obtained from postnatal 
0-2 day SD rats. Retinal cell cultures were prepared using 
rat eyes as described [7].
 The rats were anesthetized with 
ether and the eyes were removed. Under a stereo-
microscope, the neuroretinas were carefully dissected free 
from the pigmented epithelium and optic nerve, and placed 
in HBSS. Tissues were cut into 2×2×2 mm sizes with a 
knife, transferred into 2 mL of papain in a conical tube, and 
incubated for 40 minutes at 37℃. After incubation, the cells 
were added to Eagle's MEM containing 3 mL FBS, 0.1 mL 
0.2% DNase I, and pipetted 20 times with a pasteur pipette. 
Cells were centrifuged at 1000 rpm for 8 minutes, the super-
natant was decanted, and the cell pellets were resuspended 
in 3 mL medium and centrifuged again at 1000 rpm for 8 
minutes. The pellets were resuspended in 2 mL medium and 
the cells were plated in 24-well tissue culture plates on 12 
mm coverslips or 10 cm dishes that had been pre-treated 
overnight with poly-D-lysine (100 ug/mL). The cells were 
maintained in Eagle's MEM with 10% FBS, 10% glucose, 
and 2 mg/mL gentamicin.
The cultured cells were divided into three groups: nor-
moxia (N), hyperoxia (H), and hyperoxia+resveratrol (5 
ug/mL, HR). The N group was placed in a 5% CO2 incubator, 
and the H and the HR groups were placed in a 5% CO2 in-
cubator with 100% O2 for 6 hours. All groups except the N 
group were treated with drugs before hyperoxic insult.
MTT assay
The MTT assay was used to estimate cell viability and 
growth as originally described by Mosmann [17]. MTT was 
dissolved at a concentration of 5 mg/mL. Ten µL of the 5 
mg/mL MTT stock solution was added to each well. After 
four hours of incubation at 37℃, the media were removed 
and 100 µL of lysing buffer (dimethyl sulfoxide, DMSO; 
95% ethanol=1:1) was added. Absorbance of the samples 
was read at 492 nm using a microtiter plate enzyme-linked 
immunosorbent assay (ELISA) reader. The amount of for-
mazan produced was proportional to the number of live and 
metabolically active cells.
Immunofluorescence assays
To measure immunofluorescence (IF), cultured cells 
were first washed twice with PBS and fixed with 4% paraf-
ormaldehyde at 4℃ for 30 minutes. The cells were washed 
twice more with 1×PBS and incubated with 1% BSA at 
room temperature for one hour. The cells were then in-
cubated with IRBP antibody for two hours and washed 
three times with PBS. Washed cells were treated with fluo-
rescence-conjugated secondary antibodies for one hour.
Rat retinal protein extraction
Pup rats of the in vivo OIR model were sacrificed at P21. 
The eyes were removed, eye cups were dissected, and ante-
rior segments and neuroretina were detached, frozen in liq-
uid nitrogen, and stored at -70℃ until further use. Frozen 
tissues were homogenized in protein lysis buffer containing 
complete protease inhibitor cocktail tablets, 1 M Tris-HCl 
(pH 8.0), 5 M NaCl, 10% Nonidet P-40, and 1 M 1,4-di-
thio-DL-threitol (DTT). After incubation for 20 minutes on 
ice, the samples were centrifuged at 12,000 rpm at 4℃ for 
30 minutes and the supernatants were transferred to new 
tubes. Total proteins were measured with a Bio-Rad 
Bradford kit (Bio-Rad Laboratories, Hercules, CA, USA).
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blot analysis
Equal amounts of proteins (30 µg) were subjected to 6% 
or 12% SDS-PAGE after denaturing in 5×SDS gel-loading 
buffer (60 mM Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 
14.4 mM 2-mercaptoehanol, and 0.1% bromophenol blue) 
in boiling water for 10 minutes. After electrophoresis, pro-
teins were electrotransferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore, Bedford, MA, USA) at a 
constant voltage of 10 V for 30 minutes. After transfer, the 
membrane was washed twice with 1×Tris-buffered saline 
(TBS) plus 0.1% Tween-20 (TBST, pH 7.4) and pre-
incubated with a blocking buffer (5% nonfat dry milk in 
TBST) at room temperature for 1 hour. The blots were then 
incubated with rabbit polyclonal iNOS, rabbit polyclonal 
eNOS, and rabbit polyclonal nNOS primary antibodies at 
1:1000 dilutions in TBST at 4℃ overnight. Following pri-
mary antibody incubations, the blots were incubated with 
secondary anti-rabbit or anti-mouse antibody (Santa Cruz 
Biotechnology) conjugated with horseradish peroxidase at 
1:2000 dilution at room temperature for one hour. Finally, 
the membrane was washed and developed using ECL plus 
or SUPEX reagents. The intensities of the western blot 
bands were measured using a densitometer (Multi Gauge WT Kim and ES Seo. Resveratrol Effect on Oxygen-induced Retinopathy
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Fig. 1. Morphologic analysis after H&E staining revealed changes in the major retinal layers of 21-day-old Sprague-Dawley rats. (A) The N 
group did not show any retinal pathology. (B) In striking contrast, the H group presented retinal lesions displaying retinal neovascularization, 
fibrovascular growth, and large areas with blood vessel leakage like retinal detachment. (C) The HR group shows a few holes which are not 
retinal detachment. N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol; OSL=outer segment layer; ISL=inner segment layer; 
ONL=outer nuclear layer; OPL=outer plexiform layer; INL=inner nuclear layer; IPL=inner plexiform layer; GCL=ganglion cell layer; 
ILM=inner limiting membrane. 
Table 1. Primer pairs and annealing temperatures for real-time PCR
Name Primer Sequence (5'-3') Annealing (℃) Amplicon size (bp)
iNOS F: AGGCTTGGGTCTTGTTAGCCTAGT 55 270
iNOS R: ATTCTGTGCAGTCCCAGTGAGGAA 55 270
eNOS F: GGATTCTGGCAAGACCGATTAC 57 159
eNOS R: GGTGAGGACTTGTCCAAACACT 57 159
nNOS F: CCTTCCGAAGCTTCTGGCAACAGC 59 474
nNOS R: TGGACTCAGATCTAAGGCGGTTGG 59 474
iNOS=inducible nitric oxide synthase; eNOS=endothelial nitric oxide synthase; nNOS=neuronal nitric oxide synthase.
Software; Fuji Photofilm, Tokyo, Japan).
RNA extraction and real-time PCR
Total RNA was extracted from tissue with TRIzol reagent 
(Invitrogen Corporation, Carlsbad, CA, USA). Briefly, total 
tissue or cells were homogenized in 1 mL of TRIzol reagent. 
Total RNA was separated from DNA and proteins by adding 
chloroform and was precipitated using isopropanol. The pre-
cipitate was washed twice in 100% ethanol, air-dried, and 
re-diluted in diethyplyrocarbonate (DEPC)-treated distilled 
water. The amount and purity of extracted RNA was quanti-
tated by spectrophotometry (GeneQuant
TM pro RNA/DNA 
calcular; GE Healthcare, Piscataway, NJ, USA), and the 
RNA was stored at -70℃ pending further processing. For re-
verse transcription, total RNA (2 µg) was reverse transcribed 
for one hour at 37℃ in a reaction mixture containing 20 U 
RNase inhibitor (Promega, Madison, WI, USA), 1 mM dNTP 
(Promega), 0.5 ng oligo-(dT) 15 primer (Promga), 1× ReT buf-
fer and 200 U M-MLV reverse transcriptase (Promega). The 
reaction mixture was then incubated at 95℃ for five minutes 
to stop the reaction. The cDNA was stored at -20℃ until fur-
ther processing.
Real-time PCR was performed in 48-well PCR plates 
(Mini Opticon
TM Real-Time PCR System; Bio-Rad) using 
Finnzymes DyNAmo SYBR green qPCR kit (Finnzymes, 
Beverly, MA, USA). Amplification conditions are shown in 
Table 1. It was the same for all apoptotic and oxidant 
mRNA assayed: 95℃ for 15 minutes, followed by 40 cycles 
of 95℃ for 45 seconds, annealing temperature for 45 sec-
onds, and 72℃ for 45 seconds. Real-time PCR data were 
analyzed with LightCycler software (Bio-Rad).
Statistical analysis
Data were expressed as mean±SD, analyzed by means of 
analysis of variance, and further assessed by Student’s 
t-tests. p<0.05 were considered significant.
Results
Morphologic changes in the in vivo OIR model 
The N group did not show any ocular pathology (Fig. Korean J Ophthalmol Vol.24, No.2, 2010
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Fig. 2. (A)Western blots for inducible nitric oxide synthase (iNOS), endothelia nitric oxide synthase (eNOS), and neuronal nitric oxide syn-
thase (nNOS) in the in vivo oxygen-induced retinopathy (OIR) were revealed. Relative expressions of iNOS (B), eNOS (C), and 
nNOS (D) in the N, H, and HR groups were revealed. The HR group was administered with 30 mg/kg of resveratrol before a hyperoxic insult. 
N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol. *p<0.05, statistically significant.
1A). In contrast, the H group had retinal lesions in the inner 
nuclear layer (INL), the ganglion cell layer (GCL), and the 
inner limiting membrane (ILM) retinal layers, displaying 
retinal neovascularization, fibrovascular growth, and large 
areas with blood vessel leakage, such as retinal detachment 
(Fig. 1B). In the HR group (Fig. 1C), a few holes were not-
ed, but retinal detachments had subsided.
 
The expressions of iNOS, eNOS, and nNOS by western 
blot analysis in the in vivo OIR model 
The expression of iNOS was reduced in the H group 
when compared to the N group, and was increased in the 
HR group when compared to the H group (p<0.05). In con-
trast, the expressions of eNOS and nNOS were increased in 
the H group compared to the N group, and were decreased 
in the HR group compared to the H group (p<0.05) (Fig. 2).
The expressions of iNOS, eNOS, and nNOS mRNA by 
real-time PCR analysis in the in vivo OIR model 
The expression of iNOS mRNA was reduced in the H 
group compared to the N group, and was increased in the 
HR group compared to the H group (p<0.05). In contrast, 
the expressions of eNOS and nNOS mRNA were increased 
in the H group compared to the N group, and was decreased 
in the HR group compared to the H group (p<0.05) (Fig. 3).
Cell viability in the in vitro OIR model 
By measuring the relative cell viability determined by the 
MTT assay in different concentrations, ranging from 5-100 
ug/mL. the optimal concentration of resveratrol was 5 
ug/mL, therefore, we used 5 ug/mL of resveratrol in the ex-
periment (Fig. 4). 
Morphologic changes from cell damage in the in vitro OIR 
The cultured retinal cells were observed using fluo-
rescence microscopy with photoreceptor marker, IRBP un-
der high magnification (×200) (Fig. 5A). Cultured retinal 
cell growth was observed with a phase contrast microscope 
(×100). Cells in the N group (Fig. 5B) appeared normal, 
whereas cells in the H group (Fig. 5C) showed cellular 
swelling with indistinct nuclear shapes. Cells in the HR 
group (Fig. 5D) had a similar appearance to the N group.
 
The expressions of iNOS, eNOS, and nNOS by western 
blot analysis in the in vitro OIR 
The expression of iNOS was reduced in the H group 
when compared to the N group, and was increased in the WT Kim and ES Seo. Resveratrol Effect on Oxygen-induced Retinopathy
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Fig. 3. Real-time PCR for inducible nitric oxide synthase (iNOS), 
endothelia nitric oxide synthase (eNOS), and neuronal nitric oxide 
synthase (nNOS) in the in vivo oxygen-induced retinopathy (OIR) 
were revealed. Relative expressions of iNOS (A), eNOS (B), and 
nNOS (C) in the N, H, and HR groups were revealed. The HR group 
was administered with 30 mg/kg of resveratrol before a hyperoxic 
insult. 
N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol. 
*p<0.05, statistically significant.
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MTT assay
Fig. 4. Resveratrol attenuation in the in vivo oxygen-induced retin-
opathy (OIR). Cultured dispersed retinal cells were prepared with 
different concentrations of resveratrol for 30 min before hyper-
oxic insult for 6 hours. Cell viability was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) 
assay. The concentrations of the drugs were 5, 10, 50 and 100 ug/mL.
N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol. 
*p<0.05, statistically significant vs. N.
Fig. 5. (A) Immunofluorescence of photoreceptor marker IRBP (in- 
terphotoreceptor retinoid-binding protein) using a fluorescence mi-
croscope under high magnification (normoxia group, ×200), and 
photomicrographs of cultured dispersed retinal cells with a phase 
contrast microscope (×100). The N (B), H (C), and HR (D) groups were
revealed. N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol.
HR group compared to the H group (p<0.05). In contrast, 
the expressions of eNOS and nNOS were increased in the H 
group compared to the N group, and were decreased in the 
HR group compared to the H group (p<0.05) (Fig. 6).
The expressions of iNOS, eNOS, and nNOS mRNA by 
real-time PCR analysis in the in vitro OIR 
The expression of iNOS mRNA was reduced in the H 
group compared to the N group, and was increased in the 
HR group compared to the H group (p<0.05). In contrast, 
the expressions of eNOS and nNOS mRNA were increased 
in the H group compared to the N group, and were de-
creased in the HR group compared to the H group (p<0.05) 
(Fig. 7).Korean J Ophthalmol Vol.24, No.2, 2010
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Fig. 6. (A) Western blots for inducible nitric oxide synthase (iNOS), endothelia nitric oxide synthase (eNOS), and neuronal nitric oxide syn-
thase (nNOS) in the in vitro oxygen-induced retinopathy (OIR) were revealed. Relative expressions of iNOS (B), eNOS (C), and 
nNOS (D) in the N, H, and HR groups were revealed. The HR group was administered with 5 ug/mL of resveratrol before a hyperoxic insult. 
N=normoxia; H=hyperoxia; HR=hyperoxia+resveratrol. *p<0.05, statistically significant.
Discussion
ROP is a unique pattern of oxygen toxicity that can lead 
to retinal detachment and blindness in preterm infants who 
are born at less than 36 weeks of gestation. ROP was first 
described in 1942 (then termed RLF) as fibroblastic over-
growth of persistent vascular sheath behind each crystalline 
lens in extreme prematurity [18,19]. RLF was developed in 
preterm infants in 1949 [20]. Oxygen therapy became avail-
able in clinical practice and intensive oxygen therapy be-
came known as a cause of RLF by 1952. In 1956, RLF was 
thought to develop in preterm infants after exposure to high 
concentrations of oxygen [21]. After the pathogenesis and 
clinical features of ROP became better understood, re-
stricted oxygen therapy monitoring of oxygen levels lead to 
a dramatic decrease in the incidence of ROP. In the 1970s 
and 1980s, the development of techniques to continuously 
monitor oxygen, together with improved ventilators with 
better control of the inspired oxygen content, enabled arte-
rial oxygen to be maintained within safe limits [22]. 
However, advances in neonatal care have to led improved 
survival rates in premature infants and concomitantly to in-
creased incidence of ROP. Therefore, ROP has re-emerged 
as a significant clinical problem in premature infants [23].
ROP progresses in two phases, vasculogenesis and angio-
genesis [24]. Phase I of ROP begins with delayed retinal 
vascular growth after birth and partial regression of existing 
vessels, i.e., vasculogenesis or the formation of blood ves-
sels from endothelial precursor cells. By 14-15 weeks of 
gestational age, mesenchymal derived spindle cells grow 
into the superficial layer of the retina from the optic nerve. 
They migrate anteriorly, towards the retinal periphery and 
develop posteriorly, into primitive vascular tubes in which 
blood cells may be seen. They are not seen after 21 weeks of 
gestational age. Phase II of ROP begins with hypoxia-in-
duced pathological vessel growth, i.e., angiogenesis or the 
development of new blood vessels by budding from exist-
ing blood vessels. From 17-18 weeks of gestational age, 
networks of capillaries form by angiogenesis and retinal 
vessels develop. From 25 weeks of gestational age, retinal 
capillaries have numerous arcades connecting arterial and 
venous vessels. VEGF is primarily secreted by retinal as-
trocytes and by Muller cells. Retinal astrocytes are closely 
associated with endothelial cells in the developing retinal 
vasculature. VEGF stimulates endothelial cell angiogenesis. 
Excessive oxygen contributes to ROP through regulation of 
VEGF. Suppression of VEGF by oxygen in phase I of ROP 
inhibits normal vessel growth, whereas elevated levels of 
VEGF induced by hypoxia in phase II of ROP precipitate 
pathological vessel proliferation. IGF-1 is a critical non- 
oxygen-regulated factor in ROP. The serum levels of IGF-1 
in premature babies directly correlate with the severity of WT Kim and ES Seo. Resveratrol Effect on Oxygen-induced Retinopathy
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Fig. 7. Real-time PCR for inducible nitric oxide synthase (iNOS), endo-
thelial nitric oxide synthase (eNOS), and neuronal nitric oxide synthase 
(nNOS) in the in vitro oxygen-induced retinopathy (OIR) were revealed. 
Relative expressions of iNOS (A), eNOS (B), and nNOS (C) in the N, 
H, and HR groups were revealed. The HR group was administered with 
5 ug/mL of resveratrol before a hyperoxic insult. N=normoxia; H=hy-
peroxia; HR=hyperoxia+resveratrol. *p<0.05, statistically significant.
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clinical ROP. IGF-1 acts indirectly as a permissive factor by 
allowing maximal VEGF stimulation of vessel growth. 
Lack of IGF-1 in preterm infants prevents normal retinal 
vascular growth in phase I of ROP, despite the presence of 
VEGF. As infants mature, rising levels of IGF-1 in phase II 
of ROP allows VEGF stimulated pathological neovasculari- 
zation. These findings suggest that restoration of IGF-1 to 
normal levels might be useful in preventing ROP in preterm 
infants. Angiogenesis appears to be driven by relative tissue 
hypoxia. HIF-1 is a nuclear protein that acts as a tran-
scription factor for VEGF. HIF is rapidly degraded in nor-
mal tissue conditions, but the turnover time is prolonged in 
hypoxic conditions, leading to increased levels within the 
nucleus. Any postnatal factor that reduces HIF levels, such 
as the relative hyperoxia produced by oxygen therapy, will 
lead to reduced, and therefore delayed, angiogenisis-medi-
ated retinal vascular development. At least one of the HIF 
proteins may be involved in the development of ROP 
[23,25,26].
Rat pups are immature at birth, and developmentally 
equivalent to a neonate born prematurely at 28 weeks po- 
stmenstrual age [23].
 The first 14 days of a rat pup's life is 
equivalent to the period of 28 weeks to 40 weeks post-
menstrual age in a human infant [23].
The pathogenesis of ROP was not well understood in ear-
ly ROP animal models. Kitten models at that time were sub-
jected to continuous high levels of oxygen. Retinal vaso- 
obliteration occurred and when they returned to room air 
following exposure to oxygen, a vasoproliferative response 
was observed. However, these extreme conditions were not 
accurate models of clinical ROP [27]. A rat pup model was 
developed in order to better understand the pathogenesis of 
ROP using this information. The "Edinburgh" model oxy-
gen paradigm consisted of a fluctuating oxygen profile de-
rived from the case of an infant who developed stage 4 ROP. 
In a rat pup model, a fluctuating oxygen atmosphere alone 
could produce retinal vasculature abnormalities similar to 
those seen in clinical ROP. Thus, ROP may be explained in 
terms of exposure of the developing retinal vasculature to 
an abnormal oxygen environment. No other insult is neces-
sary [28].
Retinal cell cultures were prepared using rat eyes as de-
scribed by Seigel [7]. Since dispersed retinal cell cultures 
from postnatal rats are removed from the orderly structure 
of the intact retina, identification of these dispersed cells is 
paramount. In the dispersed rat embryonic retinal cell mon-
olayer culture, flat cells and neuronal-like cells are evident, 
however, morphology alone is not enough to identify each 
of the six major phenotypes of the neuroretina: ganglion, bi-
polar, photoreceptor, amacrine, horizontal, and Müller 
cells. With the advent of retina specific antibodies, specific 
retinal cell types could be identified in vitro on the basis of 
retina-specific marker expression, rather than on less-reli-
able morphological characteristics [29].
Photoreceptor enrichment is also possible through the 
chemical destruction of undesired retinal neurons by the 
photoreceptor-sparing toxins kainic acid and ß-bungarotox-
in [30] and by the non-ionic detergent Triton X-100 [31]. 
Mechanical selection through the adept use of a vibratome 
has been used as a physical means of photoreceptor purifi-Korean J Ophthalmol Vol.24, No.2, 2010
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cation [32]. Retinal neurons have been shown to express 
proteins immunoreactive with glial markers (GFAP, S-100, 
and vimentin), photoreceptor markers (IRBP, S-Ag, recov-
erin), ganglion cell marker (2G12), as well as Müller cell 
marker (RetG1) [33].
 Photoreceptors-immunolabeled with 
IRBP antibody-represented the major population of neuro-
nal cells and consisted of approximately 65% rods and 35% 
cones (of total photoreceptors). In primary retinal cell cul-
tures, the photoreceptors were mainly rods and represented 
the most abundant population in addition to Muller cells 
[34]. The MTT assay was used for estimation of cell via-
bility and growth, as originally described by Mosmann [17].
To identify photoreceptors of retinal cells, the immuno-
fluorescence assay photoreceptor marker, IRBP, was used. 
Cells in the N group appeared normal, whereas cells in the 
H group showed cellular swelling with indistinct nuclear 
shapes. Cells in the HR group had a similar appearance to 
those in the N group. Morphologically, damaged cells in the 
in vitro OIR were subsided according to administration of 
resveratrol. 
NO, a cellular signaling molecule, is synthesized during 
the stoichiometric conversion of L-arginine to L-citrulline 
in the presence of oxygen and nicotinamide adenine dinu-
cleotide phosphate (NADPH), which is catalyzed by nitric 
oxide synthase (NOS) [35]. NO inhibits platelet ag-
gregation [36], inhibits platelets [37], and inhibits poly-
morphonuclear neutrophils [38]. NO is known as a vaso-
dilator [39] and exerts a neuroprotective effect in stoke 
models [40]. Three isoforms of NOS that were named by 
the tissue are first cloned. Neuronal NOS (nNOS; 157 kDa) 
and endothelial NOS (eNOS; 140 kDa) are constitutively 
expressed and calcium-dependent, whereas inducible NOS 
(iNOS; 135 kDa) is expressed after immunologic challenge 
and neuronal injury, and is calcium-dependent under most 
circumstances. The eNOS and nNOS are present under 
physiological conditions, whereas iNOS is expressed in re-
sponse to immunological stimulation. Additionally, eNOS 
produces NO with beneficial effects, such as vasodilative 
effect, antiplatelet aggregation effect, and inhibits PMN ad-
hesion, whereas nNOS and iNOS produce NO with delete-
rious effects [41,42]. Generally, in the hypoxic injury of 
neurons, the expression of iNOS increased but those of 
eNOS and nNOS decreased. The expression of NOS iso-
forms after damage still remains controversal. 
Resveratrol exhibits anti-inflammatory activity by in-
hibition of inflammatory mediators [43]. Resveratrol has 
anti-cancer activity and interferes with stages of carcino-
genesis, including initiation, promotion, and progression 
[44].
 Resveratrol also possesses antioxidant effects [45] and 
has anti-angiogenic properties. Resveratrol has direct in-
hibitory action on cardiac fibroblasts and may inhibit the 
progression of cardiac fibrosis, which has beneficial car-
diovascular effects. Resveratrol is considered a potential 
neuroprotective agent in treating focal cerebral ischemia in-
jury, Huntington's disease, and Alzheimer's disease [46]. 
Recently, resveratrol was found to protect the spinal cord, 
kidney,
 and heart from ischemia-reperfusion injury through 
upregulation of NO [47]. Resveratrol has been reported to 
either suppress [48] or enhance NO production [49].
 
Resveratrol inhibits NOS activity and modifies iNOS ex-
pression [50]. Resveratrol may inhibit cell proliferation 
through the up-regulation of eNOS transcripts and the sub-
sequent activation of p53 [51].
Resveratrol has several effects on retinal injury. Resveratrol 
reduces oxidation and proliferation of human retinal pig-
ment epithelial cells via extracellular signal-regulated kin-
ase inhibition [52]. Resveratrol exerts its antiproliferative 
effect on HepG2 hepatocellular carcinoma cells by induc-
ing cell cycle arrest and NOS activation [53].
The mechanism by which resveratrol exerts its health- 
promoting effects is not yet fully elucidated in either in vivo 
or in vitro OIR. Our data showed that the expression of 
iNOS and/or mRNA in both in vivo and in vitro OIR accord-
ing to administration of resveratrol was more reduced in the 
H group than in the N group and was increased in the HR 
group compared to the H group. However, the expression of 
eNOS and nNOS and/or mRNA was reverse as compared to 
those of iNOS. The data is similar to our previous report on 
the neuroprotective effects on hypoxic-ischemic encephal-
opathy [15]. In the present study, both in vivo and in vitro 
OIR revealed the same result, possibly because we used ret-
inal cell enriched neurons. 
In conclusion, resveratrol exerts some protective effects 
via modulation of NO-mediated mechanisms in both in vivo 
and in vitro OIR models.
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